Simplified Reversed Chloroquines To Overcome Malaria Resistance to Quinoline-Based Drugs by Gunsaru, Bornface et al.
Portland State University 
PDXScholar 
Chemistry Faculty Publications and 
Presentations Chemistry 
5-2017 
Simplified Reversed Chloroquines To Overcome 
Malaria Resistance to Quinoline-Based Drugs 
Bornface Gunsaru 
Portland State University 
Steven J. Burgess 
Portland State University 
Westin Morrill 
DesignMedix, Inc., 
Jane X. Kelly 
Portland State University 
Shawheen Shomloo 
Portland State University 
See next page for additional authors 
Follow this and additional works at: https://pdxscholar.library.pdx.edu/chem_fac 
 Part of the Chemistry Commons, Medicinal and Pharmaceutical Chemistry Commons, and the 
Microbiology Commons 
Let us know how access to this document benefits you. 
Citation Details 
Gunsaru B, Burgess SJ, Morrill W, Kelly JX, Shomloo S, Smilkstein MJ, Liebman K, Peyton DH. 2017. 
Simplified reversed chloroquines to overcome malaria resistance to quinoline-based drugs. Antimicrob 
Agents Chemother 61:e01913-16. 
This Article is brought to you for free and open access. It has been accepted for inclusion in Chemistry Faculty 
Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make 
this document more accessible: pdxscholar@pdx.edu. 
Authors 
Bornface Gunsaru, Steven J. Burgess, Westin Morrill, Jane X. Kelly, Shawheen Shomloo, Martin J. 
Smilkstein, Katherine May Liebman, and David H. Peyton 
This article is available at PDXScholar: https://pdxscholar.library.pdx.edu/chem_fac/194 
Simplified Reversed Chloroquines To
Overcome Malaria Resistance to
Quinoline-Based Drugs
Bornface Gunsaru,a Steven J. Burgess,a,b Westin Morrill,b Jane X. Kelly,a,c,b
Shawheen Shomloo,a,b† Martin J. Smilkstein,c Katherine Liebman,a
David H. Peytona,b
Department of Chemistry, Portland State University, Portland, Oregon, USAa; DesignMedix, Inc., Portland,
Oregon, USAb; Portland Veterans Affairs Medical Center, Portland, Oregon, USAc
ABSTRACT Building on our earlier work of attaching a chemosensitizer (reversal
agent) to a known drug pharmacophore, we have now expanded the structure-
activity relationship study to include simplified versions of the chemosensitizer. The
change from two aromatic rings in this head group to a single ring does not appear
to detrimentally affect the antimalarial activity of the compounds. Data from in vitro
heme binding and -hematin inhibition assays suggest that the single aromatic RCQ
compounds retain activities against Plasmodium falciparum similar to those of CQ, al-
though other mechanisms of action may be relevant to their activities.
KEYWORDS chloroquine, Plasmodium falciparum, antimalarial, drug discovery,
accumulation, hemozoin, hematin, structure-activity relationship, drug development,
malaria, drug resistance
Malaria remains a major health problem, mainly in sub-Saharan Africa and parts ofAsia and South America (1, 2), with over 200 million clinical infections and nearly
half a million deaths annually (3). Malaria is caused by protozoan parasites belonging
to the genus Plasmodium and is transmitted via the bite of a female Anopheles
mosquito (4, 5). There are four major species of the parasite that cause malaria in
humans, namely, Plasmodium falciparum, P. vivax, P. ovale, and P. malaria, while a fifth
parasite, P. knowlesi, is now recognized (6, 7).
Historically, a range of drugs has been used to treat or prevent malaria (8–11),
including several derived from the quinoline ring system. Examples include quinine,
chloroquine (CQ), amodiaquine, piperaquine, mefloquine, and primaquine. All of these
drugs have been suggested to act on the blood stages of the parasite’s life cycle (12)
except primaquine, an 8-aminoquinoline, which acts on the hepatic stage (13, 14).
CQ was introduced in the mid-20th century and quickly became the most important
of the blood-stage-acting quinoline class of drugs. In addition to being generally safe,
effective, and inexpensive, CQ could be used to treat children and pregnant women,
who account for most of the deaths associated with malaria. However, resistance to CQ
was reported as early as 1957 (15, 16), and today it is so widespread that CQ has been
rendered almost ineffective as a therapy (17). CQ resistance is strongly correlated with
mutations in the membrane protein P. falciparum chloroquine resistance transporter
(PfCRT), located in the parasite’s digestive vacuole (DV), the location of CQ’s major
antimalarial mode of action (18–21). There is evidence that CQ’s accumulation in the DV
is reduced in CQ-resistant (CQR) parasites, which has been implicated as a cause of the
resistance (18, 19). PfCRT from CQR P. falciparum strains has been shown to be able to
transport CQ, signifying a direct mechanistic link to CQR (22).
However, verapamil, a calcium channel blocker, is able to block CQ transport by
PfCRT (22) and has been shown to be able to reverse CQR in P. falciparum (23, 24).
Received 2 September 2016 Returned for
modification 27 September 2016 Accepted
22 January 2017
Accepted manuscript posted online 13
February 2017
Citation Gunsaru B, Burgess SJ, Morrill W, Kelly
JX, Shomloo S, Smilkstein MJ, Liebman K,
Peyton DH. 2017. Simplified reversed
chloroquines to overcome malaria resistance
to quinoline-based drugs. Antimicrob Agents
Chemother 61:e01913-16. https://doi.org/
10.1128/AAC.01913-16.
Copyright © 2017 Gunsaru et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.





May 2017 Volume 61 Issue 5 e01913-16 aac.asm.org 1Antimicrobial Agents and Chemotherapy
 on A





















Certain tricyclic antidepressants (25), antihistamines (26), and some antiretroviral pro-
tease inhibitors (27–29) also possess this ability. A three-dimensional QSAR pharmaco-
phore model for these chemosensitizers, or reversal agents (RAs), was developed, and
it indicated that two aromatic hydrophobic interaction sites linked by an aliphatic chain
to a hydrogen bond acceptor site (generally nitrogen) were required for activity (30). A
hybrid “reversed-chloroquine” (RCQ) (Fig. 1) molecule was subsequently synthesized in
our laboratory, consisting of a CQ-like moiety linked to an RA-like moiety (31). Due to
the potency of this hybrid drug (50% inhibitory concentration [IC50] for CQ-sensitive
[CQS] D6 and CQR Dd2 of 2.9 nM and 5.3 nM, respectively), work was started on the
synthesis of related compounds in order to investigate the structure-activity relation-
ship (SAR) (32, 33). Compounds 2 and 3 (Fig. 1) are two examples of the compounds
generated during those studies; these compounds illustrate some of the changes to
both the RA head group and the linker between the CQ-like moiety and the RA head
group. Note that both examples retain the two aromatic rings in the RA head group, as
suggested by the published pharmacophore (30). Others have recently reported efforts
in developing similar CQ hybrid drug-like molecules (34).
There is a continuing need for the development of new but inexpensive malaria
drugs with minimal toxicity or side effects, because the Plasmodium parasites continue
to develop resistance to current chemotherapies, including even those of the artemis-
inin class (35, 36). The loss of the clinical usefulness of CQ, with its few side effects, high
safety, high efficacy, and extremely low cost, is particularly regrettable.
Here, we report on RCQ-like molecules with a simplified head group moiety, having
only a single aromatic ring, in order to investigate the possibility of lowering the cost
of goods, simplifying syntheses, and/or increasing solubility. These new compounds
FIG 1 Evolution of the reversed chloroquine molecules. Highlighted in boldface are the two aromatic
rings and the hydrogen bond acceptor of the reversal agent moiety. These are the key elements of the
reversal agent pharmacophore, as identified by Bhattacharjee et al. (30).
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therefore deviate from the published pharmacophore RA (30). However, and perhaps
surprisingly, this set of simplified compounds generally has a marked improvement in
potency that may lead to drugs with reduced dosages, lowered cost, and reduced
toxicity.
RESULTS
The syntheses of compounds 4, 5, and 16 have been previously described (31, 33).
Syntheses of other compounds are shown in Fig. 2. Compounds 6 to 15 and 18 to 23
were synthesized by treating compound 5 with the appropriate commercially available
piperazine analogues. Compounds 17 and 24 to 27 were prepared by treating com-
pound 16 with the appropriate halide in the presence of base.
Compounds 1 to 3 have good activity against both CQS and CQR P. falciparum, with
the RA head group remaining faithful to our starting-point pharmacophore: a triangular
orientation of the aromatic rings and nitrogen-hydrogen bond acceptor (e.g., com-
pound 1, as illustrated in Fig. 3). We decided to investigate whether this orientation of
the two RA aromatic rings was important for activity. Thus, compounds 6 to 8 were
synthesized, having the orientation of the rings systematically changed until a linear
arrangement was reached. The in vitro activities of these compounds were still good,
and in the case of compound 8 they were surprisingly good, with low- to sub-nanomolar
IC50s for each of the three strains tested (Table 1 and Fig. 4). As the linear orientation
of the rings in compound 8 was quite different from the starting-point pharmacophore
FIG 2 Synthetic approaches to the simplified reversed chloroquine molecules. Reagents and conditions included the following: (i) 3-aminopropanol,
130°C, 48 h; (ii) methanesulfonyl chloride, dichloromethane, Et3N, 0°C, 0.5 h; (iii) THF, Et3N, and reflux for 96 h, or acetonitrile, K2CO3, and reflux
for 96 h; (iv) piperazine, THF, and reflux for 24 h; (v) halide compound, acetonitrile, K2CO3, and reflux.
FIG 3 Changes in the orientation of the rings in the RA head group. The circles indicate how the
orientation of the aromatic rings differs from the pharmacophore model.
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TABLE 1 Structures, ClogP, IC50, and cytotoxicity and therapeutic index values for CQ and synthesized compounds
Compound Structure ClogPb
IC50 (nM) for P. falciparuma Cytotoxicityg
(nM) T.I.hD6 Dd2 7G8
CQ 5.1 6.9 102 108 12,000 1,700
1d 8.9 2.9 5.3 4.0 700 240
2e 5.9 14 16 NDc 62,000 4,400
3f 7.4 1.9 2.6 11 1,100 580
6 7.0 1.2 2.6 ND 1,700 1,400
7 7.0 0.9 1.8 ND 2,100 2,300
8 7.0 0.6 0.9 0.2 2,200 3,700
9 5.2 0.4 0.7 0.6 6,400 16,000
10 6.6 0.3 0.5 0.1 ND
11 6.0 2.0 0.2 0.2 ND
12 5.7 1.3 0.3 0.3 ND
(Continued on following page)
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IC50 (nM) for P. falciparuma Cytotoxicityg
(nM) T.I.hD6 Dd2 7G8
13 6.9 0.06 0.2 0.3 ND
14 5.8 0.9 0.8 0.3 ND
15 6.2 0.1 1.3 0.5 ND
16f 3.4 4.3 6.8 ND 23,000 6,800
17 4.1 2.4 7.0 9.0 ND
18 5.0 0.5 1.0 1.2 ND
19 7.3 1.1 1.1 0.8 ND
20 5.0 4.0 7.0 7.0 ND
21 4.3 0.7 1.1 0.9 13,300 19,000
22 4.3 0.5 1.6 1.1 ND
23 4.1 1.4 2.3 ND 28,000 20,000
24 4.7 0.3 0.5 0.5 ND
25 5.8 0.5 0.9 1.0 ND
(Continued on following page)
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(Fig. 3), the decision was made to move even further away from that model and remove
the second ring altogether, resulting in compound 9. This did not reduce the remark-
ably potent antimalarial activity (e.g., Fig. 4, IC50 data fits) but did reduce the calculated
partition coefficient (ClogP) value to a number that is nearly that of CQ and therefore
much more “drug-like” (Table 1).
Given the surprisingly good activity of compound 9, a SAR study on the single
aromatic RA version of the RCQ compounds was initiated. Compounds 10 to 15 were
synthesized with various substituents on the single phenyl ring. While there was
some variation in results, all had IC50s below 5 nM, and many were even below 1
nM (Table 1). Further variations on compound 9 led to the introduction of a second
linker unit between the phenyl and piperazine rings (compounds 17, 18, and 20), as well
as replacing the phenyl with naphthyl and heterocyclic ring systems, and including some
substituted examples (compounds 24 to 27). None of these changes had any serious
detrimental effects on in vitro activity, and several have ClogP values lowered to below 5.
Of particular note are the pyridyl compounds 21 and 22 and the pyrimidine compound 23
(Table 1), all of which have the potential to form very water-soluble salts and may be
especially orally available.
In vitro heme binding and hemozoin inhibition. We have previously shown that,
in a simple in vitro test tube experiment, the RCQ compounds with the RA-like moiety
containing two aromatic rings bind heme and inhibit -hematin formation to an extent
similar to that of CQ (33). Applying the same tests to a selection of these single aromatic
RCQ compounds (compounds 9, 11, 12, and 13), we found that these compounds bind
to heme to a similar extent as CQ, with all compounds having dissociation constant (Kd)
values of about 5 M (CQ gives 5.4 M in our test). In the -hematin inhibition test, CQ
had an IC50 of 35 M, and the RCQ compounds all fell into the range of 5 to 43 M
(similar to CQ). These results point to the capability of these new RCQ compounds to
act against P. falciparum in a manner similar to that of CQ.
In vivo efficacy against Plasmodium yoelii. A selection of the compounds (com-
pounds 9, 10, 12, 21, 23, and 24) was tested in vivo against P. yoelii in a murine malaria
model. The compounds were first converted to water-soluble hydrochloride or phosphate
salts for administration in aqueous solution. Efficacy testing was carried out using 4
different dose levels with 5 mice at each level, administered by oral gavage. It can be seen
from Table 2 that several of the compounds, such as compounds 9 and 21, have low 50%
TABLE 1 (Continued)
Compound Structure ClogPb
IC50 (nM) for P. falciparuma Cytotoxicityg
(nM) T.I.hD6 Dd2 7G8
26 4.5 0.5 0.9 0.9 ND
27 5.7 0.3 0.5 0.4 ND
aIC50s shown are for CQS D6 and for CQR Dd2 and 7G8. Results are averages from at least 3 runs. The uncertainties were estimated to be 15%, based on weighing
uncertainties for the various compounds, as well as on variations between determinations that were performed during different weeks. In order to compare results
run on different days and with different batches of each strain, CQ was run as a positive control; the results obtained were then normalized to the CQ values of 6.9
nM for D6, 102 nM for Dd2, and 108 nM for 7G8. For example, the normalized IC50 for an RCQ compound tested against a D6 strain was determined as [6.9/IC50 CQ
(D6)]  IC50 of RCQ compound D6.
bClogP values were calculated using ChemDraw Ultra.
cND, not determined.
dBurgess et al. (31).
eAndrews et al. (32).
fBurgess et al. (33).
gCytotoxicities are against mouse spleen lymphocytes. These values are estimated to be 50%, based on weighing uncertainties for the various compounds (which
are free bases and often oils), as well as on variability between determinations that were performed during different weeks.
hT.I., therapeutic index (unitless; determined as cytotoxicity/efficacy against D6 of 12,000 for D6).
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effective dose (ED50) values, indicating they are indeed orally efficacious. A single-dose
toxicity evaluation was also performed, using 1 or 2 mice in each case. The doses were
limited by water solubilities. Using this crude screen, the lack of evident toxicity at doses as
high as 150-fold the ED50 (compound 9) suggests a favorable safety margin.
DISCUSSION
The change from two aromatic rings in the RA-like head group to a single ring does
not appear to have detrimentally affected the antimalarial activity of the RCQ com-
pounds, perhaps to a surprising extent. The data from the in vitro heme binding and
-hematin inhibition tests suggest that the single aromatic RCQ compounds can still
act against P. falciparum in a manner similar to that of CQ, although further mechanistic
testing in the parasite is required to confirm whether they actually do so (the in vitro
results cannot provide proof of this). As is the case for many drugs, whether other
mechanisms of action also are relevant to their activities remains an open question.
Nevertheless, in vivo results are very encouraging at this early stage. Several of the
compounds were evaluated for their cytotoxicity potential in a mammalian system
(Table 1). Examining the data in Table 1, it becomes apparent that there is a
correlation between ClogP and cytotoxicity. In fact, the compounds with the highest
therapeutic index (cytotoxicity/antimalarial potency ratio) are generally those com-
pounds with the lowest ClogP values (and, thus, the least lipophilic compounds). It is
notable that many of the most potent of the compounds (lowest IC50s) are the most
lipophilic but also are the most cytotoxic. Thus, the choice for moving candidates
forward in a drug development pathway would necessarily be a compromise between
such competing factors. In fact, in vivo evaluations of potencies and toxicities may be
more important than these in vitro screening tests to the selection of compounds for
further development.
There are several compounds shown in Table 2 that demonstrate good oral efficacy
FIG 4 Dose-response curves for CQ and compounds 8 and 9 against CQS D6 (a) and CQR Dd2 (b). Parasite
growth is measured in fluorescence units and normalized to the control values to give percent growth.
The best-fit curves and IC50s were calculated by Prism (GraphPad) software.
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(and potency) without evident toxicity when administered as salts in aqueous solution.
Of course, there remain many more preclinical evaluations in order to choose and
validate lead drug candidates. What this study provides is a group of very synthetically
accessible and inexpensive compounds that overcome drug resistance of well-accepted
test strains, as well as low cytotoxicity and little acute toxicity in a single mammalian
system. An encouraging step in this evaluation process is our recent report that one of
these simplified compounds, as well as a compound containing two aromatic rings,
both have good potency against ex vivo clinical isolates infected by either P. falciparum
or P. vivax malaria parasites (37).
MATERIALS AND METHODS
All chemicals were obtained from Sigma-Aldrich Chemical Co. or TCI America and were used as
supplied. Purities of all final products were 95% as determined by high-performance liquid chroma-
tography (HPLC), measured by UV detection at 254 and 325 nm with a Varian ProStar 325 UV-visible
dual-wavelength detector. HPLC was done with a Microsorb-MV 100-5 C18 250-mm by 4.6-mm column.
Elution was done with 95% methanol and 5% water with 0.1% TFA for 30 min. HPLC method C was
performed using a Supelco Ascentis C18 column (5-m volume; 4.6 mm by 150 mm), eluting with a
30-min gradient from 95:5 to 5:95 water with 0.1% (vol/vol) formic acid–acetonitrile. Retention times (tR)
are given in minutes. High-resolution mass spectrometry was performed on a Bruker micrOTOF-Q
instrument. Results were obtained using electrospray ionization mass spectrometry (ESIMS) in the
positive mode at a flow rate of 0.4 ml/min with 1:1 methanol-water. 1H, 13C, and two-dimensional nuclear
magnetic resonance (NMR) experiments were run on a Bruker 400 MHz Avance II instrument using the
standard pulse sequences provided, including zg30, zgpg30 cosygpqf, hsqcetgpsi2, hmbcgplpndqf, and
noesyph, at 25°C.
The syntheses of compounds 4, 5, and 16 have been previously described (31, 33).
General procedure A for the preparation of compounds 6 to 9, 11, 15, 18, 19, 22, and 23.
Compound 5 was added to a mixture of the respective piperazine and triethylamine (Et3N) in tetrahy-
drofuran (15 ml). The reaction mixture was allowed to reflux for 4 days, cooled, and then poured into
saturated sodium bicarbonate solution (30 ml). The resulting mixture was extracted with chloroform (3
TABLE 2 In vivo 3-day suppressive test against P. yoelii in a murine malaria model
Compound Structure ED50a (mg/kg/day) Toxicity observationb
9 2 Well tolerated at 300 mg/kg
10 8
Death at 260 mg/kg, delayed death of 2/4
mice at 64 mg/kg
12 10 Well tolerated at 500 mg/kg
21 6 Well tolerated at 435 mg/kg
23 7 Not tested at high dose
24 3 Well tolerated at 153 mg/kgc
aExperiments consisted of at least 4 doses, with 4 or 5 mice/dose. ED50s were calculated by Prism (GraphPad) software from a best-fit curve. Errors are estimated to
be 20% and reported to the nearest integer value.
bToxicity observations were obtained from single-dose experiments on 1 or 2 mice/compound.
cThis was the highest dose possible given the reduced aqueous solubility of this compound.
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times with 10 ml each time). The combined chloroform extracts were evaporated, and the crude product
was purified by recrystallization and/or chromatography.
General procedure B for the preparation of compounds 10, 12 to 14, and 21. Compound 5 was
added to a mixture of the respective piperazine and K2CO3 in acetonitrile, and the reaction mixture was
heated to reflux for 72 h. After cooling to room temperature, the solvent was removed and the residue
partitioned between water and chloroform. The organic layer was separated, washed with water, and
then dried and evaporated to leave the crude product, which was then purified by recrystallization
and/or chromatography.
N-(3-(4-(Biphenyl-2-yl)piperazin-1-yl)propyl)-7-chloroquinolin-4-amine (compound 6). The title
compound was prepared from compound 5 (0.60 g, 1.9 mmol), 1-(biphenyl-2-yl)piperazine (0.55 g, 2.29
mmol), and triethylamine (0.39 g, 3.81 mmol) according to general procedure A. The crude product was
recrystallized from methanol-ethyl acetate (25:75) to give a brown powder (0.12 g, 14%). HPLC tR  11.38
(95% pure). 1H NMR  (ppm) (DMSO-d6): 8.38 (1H, d, J  5.37 Hz), 8.22 (1H, d, J  9.04 Hz), 7.77 (1H, d,
J  2.20 Hz), 7.59 to 7.62 (2H, m), 7.40 to 7.42 (3H, m), 7.24 to 7.37 (3H, m), 7.16 to 7.21 (1H, m), 7.06 to
7.08 (2H, m), 6.46 (1H, d, J  5.45 Hz), 3.27 to 3.29 (2H, m), 2.67 to 2.89 (4H, m), 2.37 (2H, m), 2.24 to 2.38
(4H, m), 1.76 to 1.78 (2H, m). 13C NMR  (ppm) (CHCl3-d): 151.7, 150.7, 149.9, 141.0, 135.2, 134.9, 131.7,
128.9, 128.6, 128.4, 128.2, 126.8, 124.9, 123.1, 122.3, 118.0, 117.4, 98.4, 58.7, 53.7, 51.1, 44.4, 23.4. ESIMS
[M  H] calculated for C28H29ClN4 457.2151, found 457.2147.
N-(3-(4-(Biphenyl-3-yl)piperazin-1-yl)propyl)-7-chloroquinolin-4-amine (compound 7). The title
compound was prepared from compound 5 (0.60 g, 1.9 mmol), 1-(biphenyl-3-yl)piperazine (0.39 g, 3.81
mmol), and triethylamine (0.39 g, 3.81 mmol) according to general procedure A. The crude product was
recrystallized from methanol-ethyl acetate (25:75) to give a white solid (0.35 g, 18.4%). HPLC tR  11.51
(98% pure). 1H NMR  (ppm) (CHCl3-d): 8.52 (1H, d, J  5.35 Hz), 7.93 (1H, d, J  2.15 Hz), 7.82 (1H, d,
J  8.94 Hz), 7.63 to 7.58 (2H, m), 7.47 to 7.32 (5H, m), 7.24 (1H, dd, J  8.00, 2.28 Hz), 7.20 to 7.13 (2H,
m), 6.98 (1H, dd, J  8.30, 2.49 Hz), 6.36 (1H, d, J  5.41 Hz), 3.43 (2H, d, J  5.08 Hz), 3.42 to 3.37 (4H,
m), 2.77 (4H, m), 2.74 to 2.68 (2H, m), 2.05 to 1.97 (2H, m). 13C NMR  (ppm) (CHCl3-d): 160.9, 152.4, 151.6,
147.9, 145.3, 141.4, 134.6, 129.8, 129.2, 127.5, 125.3, 121.9, 122.3, 119.6, 115.4, 113.7, 112.5, 98.4, 96.4,
58.8, 53.7, 49.5, 44.1, 24. ESIMS [M  H] calculated for C28H29ClN4 457.2154, found 457.2171.
N-(3-(4-(Biphenyl-4-yl)piperazin-1-yl)propyl)-7-chloroquinolin-4-amine (compound 8). The title
compound was prepared from compound 5 (0.50 g, 1.59 mmol), 1-(biphenyl-4-yl)piperazine (0.45 g, 1.91
mmol), and triethylamine (0.32 g, 3.17 mmol) according to general procedure A. The crude product was
purified by column chromatography on silica, eluting with methanol-ethyl acetate (1:3), to give a white
solid (0.16 g, 22%). HPLC tR  10.84 (96% pure). 1H NMR  (ppm) (DMSO-d6): 8.41 (1H, d, J  5.46 Hz),
8.27 (1H, d, J  9.02 Hz), 7.79 (1H, d, J  2.25 Hz), 7.58 to 7.62 (2H, m), 7.53 to 7.55 (2H, m), 7.48 (1H, br
t, J  5.76 Hz), 7.44 (1H, dd, J  9.01, 2.34 Hz), 7.40 to 7.42 (2H, m), 7.26 to 7.27 (1H, m), 6.99 to 7.04 (2H,
m), 6.53 (1H, d, J  5.53 Hz), 3.33 to 3.38 (~2H, m), 3.18 to 3.25 (4H, m), 2.55 to 2.59 (4H, m), 2.46 to 2.50
(2H, m), 1.85 to 1.90 (2H, m). 13C NMR  (ppm) (DMSO-d6): 152.1, 150.8, 140.5, 134.0, 130.8, 129.3, 127.6,
127.6, 126.8, 126.3, 124.6, 117.9, 116.0, 99.1, 56.0, 53.2, 48.5, 41.3, 25.5. ESIMS [M  H] calculated for
C28H29ClN4 457.2154, found 457.2143.
7-Chloro-N-(3-(4-phenylpiperazin-1-yl)propyl)quinolin-4-amine (compound 9). The title com-
pound was prepared from compound 5 (0.30 g, 1.0 mmol), 1-phenylpiperazine (0.32 g, 1.2 mmol), and
triethylamine (0.27 g, 2.0 mmol) according to general procedure A. The crude product was recrystallized
from ethanol to give a cream solid (0.16 g, 44%). HPLC tR  8.28 (99% pure). 1H NMR  (ppm) (CHCl3-d):
8.51 (1H, d, J  5.35 Hz), 7.92 (1H, d, J  2.16 Hz), 7.80 (1H, d, J  8.92 Hz), 7.33 to 7.34 (3H, m), 7.20 (1H,
dd, J  8.89, 2.18 Hz), 6.96 to 7.01 (2H, m), 6.90 to 6.95 (1H, m), 6.34 (1H, d, J  5.39 Hz), 3.41 (2H, td,
J  5.93, 4.21 Hz), 3.32 to 3.33 (4H, m), 2.73 to 2.76 (4H, m), 2.69 (2H, t, J  5.41 Hz), 2.00 (2H, m). 13C
NMR  (ppm) (CHCl3-d): 152.2, 151.1, 150.5, 149.1, 134.7, 129.3, 128.7, 124.8, 122.0, 120.3, 117.4, 116.2,
98.6, 58.6, 53.7, 49.4, 44.3, 23.6. ESIMS [M  H] calculated for C22H25ClN4 381.1841, found 381.1831.
7-Chloro-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)propyl)quinolin-4-amine (compound 10). The
title compound was prepared from compound 5 (15.0 g, 47.6 mmol), 1-(4-chlorophenyl)piperazine
hydrochloride (12.22 g, 52.4 mmol), and K2CO3 (14.5 g, 104.8 mmol) in acetonitrile (150 ml) according to
general procedure B. The crude product was recrystallized from ethanol to give a solid (14 g, 71%). HPLC
tR  5.91 (98% pure). 1H NMR  (ppm) (CHCl3-d): 8.52 (1H, d, J  5.34 Hz), 7.93 (1H, d, J  2.14 Hz), 7.77
(1H, d, J  8.92 Hz), 7.29 to 7.27 (~2H, m), 7.24 (1H, br t, J  4.06 Hz), 7.20 (1H, dd, J  8.89, 2.16 Hz),
6.92 to 6.87 (2H, m), 6.35 (1H, d, J  5.38 Hz), 3.41 (2H, td, J  5.93, 4.28 Hz), 3.27 to 3.30 (4H, m), 2.72
to 2.73 (4H, m), 2.69 (2H, t, J  5.43 Hz), 2.00 (2H, m). 13C NMR  (ppm) (CHCl3-d): 152.2, 150.4, 149.7,
149.2, 134.7, 129.2, 128.8, 125.1, 124.8, 121.9, 117.4, 117.3, 98.6, 58.5, 53.5, 49.4, 44.2, 23.7. ESIMS [M H]
calculated for C22H24Cl2N4 415.1451, found 415.1460.
7-Chloro-N-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)quinolin-4-amine (compound 11). The
title compound was prepared from compound 5 (0.58 g, 1.84 mmol), 1-(4-fluorophenyl)piperazine (0.40
g, 2.21 mmol), and triethylamine (0.37 g, 3.68 mmol) according to general procedure A. The crude
product was recrystallized from methanol-ethyl acetate (25:75) to give a white powder (0.26 g, 35%).
HPLC tR  5.91 (99% pure). 1H NMR  (ppm) (CHCl3-d): 8.52 (1H, d, J  5.36 Hz), 7.93 (1H, d, J  2.16 Hz),
7.81 (1H, d, J  8.94 Hz), 7.31 (1H, br t, J  4.04 Hz), 7.21 (1H, dd, J  8.91, 2.17 Hz), 7.02 to 7.03 (2H,
m), 6.94 to 6.94 (2H, m), 6.35 (1H, d, J  5.40 Hz), 3.42 (2H, td, J  5.91, 4.26 Hz), 3.25 to 3.26 (4H, m),
2.72 to 2.77 (4H, m), 2.69 to 2.70 (2H, m), 2.00 (2H, m). ESIMS [M H] calculated for C22H24ClFN4
399.1746, found 399.1753.
7-Chloro-N-(3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl)quinolin-4-amine (compound 12). The
title compound was prepared from compound 5 (10.00 g, 31.7 mmol), 1-(4-methoxyphenyl)piperazine
dihydrochloride (9.27 g, 35.0 mmol), and K2CO3 (13.17 g, 95.3 mmol) in acetonitrile (100 ml) according
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to general procedure B. The crude product was recrystallized from ethanol to give a solid (7.2 g, 55%).
HPLC tR  6.88 (98% pure). 1H NMR  (ppm) (CHCl3-d): 8.51 (1H, d, J  5.35 Hz), 7.92 (1H, d, J  2.14 Hz),
7.83 (1H, d, J  8.92 Hz), 7.43 (1H, br t, J  4.06 Hz), 7.21 (1H, dd, J  8.88, 2.16 Hz), 6.94 to 6.98 (2H,
m), 6.89 to 6.91 (2H, m), 6.34 (1H, d, J  5.39 Hz), 3.81 (3H, s), 3.41 (2H, td, J  5.87, 4.17 Hz), 3.22 to 3.23
(4H, m), 2.73 to 2.76 (4H, m), 2.70 (2H, t, J  5.32 Hz), 1.99 (2H, m). 13C NMR  (ppm) (CHCl3-d): 154.2,
152.2, 150.5, 149.2, 145.5, 134.7, 128.7, 124.8, 122.2, 118.3, 117.5, 114.6, 98.6, 58.7, 55.6, 53.8, 50.9, 44.4,
23.6. ESIMS [M  H] calculated for C23H27ClN4O 411.1946, found 411.1949.
7-Chloro-N-(3-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)propyl)quinolin-4-amine (com-
pound 13). The title compound was prepared from compound 5 (2.03 g, 6.44 mmol), 1-(4-trifluoro-
methylphenyl)piperazine (1.63 g, 7.08 mmol), and K2CO3 (1.07 g, 7.73 mmol) in acetonitrile (30 ml)
according to general procedure B. The crude product was recrystallized from ethanol to give a solid (0.36
g, 13%). HPLC tR  5.88 (99% pure). 1H NMR  (ppm) (CHCl3-d): 8.52 (1H, d, J  5.35 Hz), 7.93 (1H, d, J 
2.16 Hz), 7.75 (1H, d, J  8.94 Hz), 7.54 (2H, d, J  8.60 Hz), 7.20 (1H, dd, J  8.90, 2.17 Hz), 7.11 (1H, s),
6.98 (2H, d, J  8.59 Hz), 6.36 (1H, d, J  5.39 Hz), 3.46 to 3.38 (6H, m), 2.74 (4H, t, J  4.91 Hz), 2.72 to
2.66 (2H, m), 2.01 (2H, p, J  5.65 Hz). ESIMS [M  H] calculated for C23H24ClF3N4 449.1714, found
449.1729.
7-Chloro-N-(3-(4-(4-nitrophenyl)piperazin-1-yl)propyl)quinolin-4-amine (compound 14). The ti-
tle compound was prepared from compound 5 (4.45 g, 14.15 mmol), 1-(4-nitrophenyl)piperazine (3.22 g,
15.57 mmol), and K2CO3 (2.15 g, 15.57 mmol) in acetonitrile (60 ml) according to general procedure B.
The crude product was recrystallized from ethanol to give a solid (5.1 g, 68%). HPLC tR  8.93 (95% pure).
1H NMR  (ppm) (CHCl3-d): 8.53 (1H, d, J  5.36 Hz), 8.14 to 8.19 (2H, m), 7.95 (1H, d, J  2.14 Hz), 7.72
(1H, d, J  8.92 Hz), 7.23 (1H, dd, J  8.88, 2.14 Hz), 6.87 to 6.89 (2H, m), 6.85 (1H, br t, J  4.14 Hz), 6.39
(1H, d, J  5.39 Hz), 3.52 to 3.53 (4H, m), 3.44 (2H, td, J  6.07, 4.46 Hz), 2.70 to 2.73 (4H, m), 2.69 (2H,
t, J  5.66 Hz), 2.01 (2H, m). 13C NMR  (ppm) (CHCl3-d): 159.7, 154.9, 141.4, 139.4, 132.7, 130.9, 129.3,
122.7, 108.4, 103.8, 96.7, 60.8, 58.6, 57.8, 51.6, 46.7, 4.8. ESIMS [M  H] calculated for C22H24Cl1N5O2
426.1691, found 426.1682.
7-Chloro-N-(3-(4-p-tolylpiperazin-1-yl)propyl)quinolin-4-amine (compound 15). The title com-
pound was prepared from compound 5 (0.70 g, 2.22 mmol), 1-(4-methylphenyl)piperazine (0.47 g, 2.67
mmol), and triethylamine (0.45 g, 4.44 mmol) according to general procedure A. The crude product was
recrystallized from methanol-ethyl acetate (25:75) to give yellow crystals (0.1 g, 12%). HPLC tR  6.67
(100% pure). 1H NMR  (ppm) (CHCl3-d): 8.51 (1H, d, J  5.35 Hz), 7.92 (1H, d, J  2.15 Hz), 7.82 (1H,
d, J  8.92 Hz), 7.41 (1H, br t, J  4.15 Hz), 7.21 (1H, dd, J  8.88, 2.17 Hz), 7.09 to 7.18 (2H, m), 6.87 to
6.92 (2H, m), 6.34 (1H, d, J  5.38 Hz), 3.41 (2H, td, J  5.89, 4.16 Hz), 3.26 to 3.29 (4H, m), 2.72 to 2.75
(4H, m), 2.69 (2H, t, J  5.33 Hz), 2.31 (3H, s), 1.98 to 1.99 (2H, m). 13C NMR  (ppm) (DMSO-d6): 152.4,
150.6, 149.6, 149.5, 133.8, 129.8, 128.0, 128.0, 124.5, 124.4, 117.9, 116.1, 99.1, 56.1, 53.4, 49.2, 41.3, 25.5,
20.5. ESIMS [M  H] calculated for C23H27ClN4 395.1997, found 395.1984.
7-Chloro-N-(3-(4-phenethylpiperazin-1-yl)propyl)quinolin-4-amine (compound 18). The title
compound was prepared from compound 5 (0.60 g, 1.91 mmol), 1-phenethylpiperazine (0.44 g, 2.28
mmol), and triethylamine (0.38 g, 3.81 mmol) according to general procedure A. The crude product was
recrystallized from ethyl acetate to give a tan solid (0.29 g, 37%). HPLC tR  9.43 (95% pure). 1H NMR 
(ppm) (CHCl3-d): 8.51 (1H, d, J  5.35 Hz), 7.94 (1H, d, J  2.14 Hz), 7.88 (1H, d, J  8.91 Hz), 7.55 (1H,
br t, J  4.04 Hz), 7.29 to 7.36 (3H, m), 7.18 to 7.29 (~3H, m), 6.33 (1H, d, J  5.39 Hz), 3.39 (2H, td, J 
5.82, 4.08 Hz), 2.74 to 2.75 (14H, m), 1.93 to 1.98 (2H, m). 13C NMR  (ppm) (CHCl3-d): 152.2, 150.6, 149.2,
140.1, 134.7, 128.7, 128.7, 128.5, 126.2, 124.7, 122.4, 117.5, 98.5, 60.7, 58.8, 53.6, 53.4, 44.5, 33.7, 23.4.
ESIMS [M  H] calculated for C23H29ClN4 409.2154, found 409.2156.
7-Chloro-N-(3-(4-(naphthalen-1-ylmethyl)piperazin-1-yl)propyl)quinolin-4-amine (compound 19).
The title compound was prepared from compound 5 (0.70 g, 2.22 mmol), 1-(naphthalene-1-
ylmethyl)piperazine (0.60 g, 2.67 mmol), and triethylamine (0.45 g, 4.44 mmol) according to general
procedure A. The crude product was recrystallized from ethyl acetate-methanol (3:1) to give yellow
crystals (0.12 g, 12%). HPLC tR  7.21 (99% pure). 1H NMR  (ppm) (CHCl3-d): 8.51 (1H, d, J  5.31 Hz),
8.33 (1H, d, J  8.36 Hz), 7.96 (1H, d, J  2.14 Hz), 7.93 (1H, d, J  8.93 Hz), 7.87 (1H, d, J  8.06 Hz), 7.81
(1H, d, J  8.10 Hz), 7.63 (1H, br t, J  4.03 Hz), 7.52 to 7.52 (3H, m), 7.43 to 7.45 (1H, m), 7.35 (1H, dd,
J  8.90, 2.17 Hz), 6.32 (1H, d, J  5.35 Hz), 4.03 (2H, s), 3.37 (2H, td, J  5.78, 4.05 Hz), 2.63 to 2.64 (10H,
m), 1.93 (2H, m). 13C NMR  (ppm) (CHCl3-d): 23.4, 44.6, 53.3, 53.7, 58.8, 61.4, 98.5, 117.5, 122.6, 124.6,
124.7, 125.2, 125.7, 125.8, 127.6, 128.2, 128.5, 128.7, 132.6, 133.6, 133.9, 134.6, 149.2, 150.6, 152.3. ESIMS
[M  H] calculated for C27H29ClN4 445.2154, found 445.2154.
N-(3-(4-Benzoylpiperazin-1-yl)propyl)-7-chloroquinolin-4-amine (compound 20). The title com-
pound was prepared from compound 5 (1.5 g, 4.8 mmol), benzoylpiperazine (0.95 g, 5.0 mmol), and
K2CO3 (0.73 g, 5.25 mmol) in acetonitrile (25 ml), according to general procedure B. The crude product
was purified by column chromatography on alumina, eluting with ethyl acetate, to give a solid (0.6 g,
30%). HPLC tR  6.81 (99% pure). 1H NMR  (ppm) (CHCl3-d): 8.53 (1H, d, J  5.36 Hz), 7.96 (1H, d, J 
2.15 Hz), 7.73 (1H, d, J  8.94 Hz), 7.42-7.43 (5H, m), 7.38 (1H, dd, J  8.91, 2.17 Hz), 6.74 (1H, br t, J 
4.39 Hz), 6.38 (1H, d, J  5.40 Hz), 3.88 (2H, br m), 3.58 (2H, br m), 3.41 (2H, td, J  6.11, 4.50 Hz), 2.63
to 2.65 (6H, m), 1.97 (2H, m). 13C NMR  (ppm) (CHCl3-d): 170.4, 152.2, 150.2, 149.2, 135.5, 134.8, 129.9,
128.9, 128.6, 127.1, 125.1, 121.3, 117.4, 98.8, 58.1, 43.7, 24.0. ESIMS [M  H] calculated for C23H25ClN4O,
409.17897, found 409.17826.
7-Chloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine (compound 21). The title
compound was prepared from compound 5 (14.80 g, 47.0 mmol), 1-(2-pyridyl)piperazine (8.44 g, 51.7
mmol), and K2CO3 (7.15 g, 51.7 mmol) in acetonitrile (150 ml) according to general procedure B. The
crude product was recrystallized from ethanol to give a solid (5.1 g, 68%). HPLC tR  5.49 (96% pure).
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1H NMR  (ppm) (CH3OH-d4): 8.39 (1H, d, J  5.64 Hz), 8.10 to 8.11 (2H, m), 7.80 (1H, d, J  2.18 Hz), 7.59
(1H, ddd, J  8.64, 7.13, 2.00 Hz), 7.40 (1H, dd, J  9.01, 2.20 Hz), 6.85 (1H, d, J  8.64 Hz), 6.71 (1H, dd,
J  7.11, 5.03 Hz), 6.59 (1H, d, J  5.69 Hz), 3.54 to 3.59 (4H, m), 3.49 (2H, t, J  6.80 Hz), 2.64 to 2.65
(4H, m), 2.61 (2H, t, J  7.10 Hz), 2.02 (2H, m). 13C NMR  (ppm) (CH3OH-d4): 152.5, 149.7, 148.5, 139.3,
136.4, 127.7, 126.0, 124.3, 118.8, 114.8, 109.2, 99.7, 57.5, 54.2, 46.5, 42.6, 26.1. ESIMS [M  H] calculated
for C21H24ClN5 382.1793, found 382.1784.
7-Chloro-N-(3-(4-(pyridin-4-yl)piperazin-1-yl)propyl)quinolin-4-amine (compound 22). The title
compound was prepared from compound 5 (0.44 g, 1.40 mmol), 1-(4-pyridyl)piperazine (0.25 g, 1.50 mmol),
and triethylamine (0.28 g, 2.80 mmol) according to general procedure A. The crude product was purified by
column chromatography on silica, eluting with ethyl acetate-methanol (1:1), to give a tan solid (0.23 g, 43%).
HPLC tR  1.72 (99% pure). 1H NMR  (ppm) (CHCl3-d): 8.52 (1H, d, J  5.33 Hz), 8.33 to 8.35 (2H, m), 7.93 (1H,
d, J  2.15 Hz), 7.72 (1H, d, J  8.93 Hz), 7.21 (1H, dd, J  8.89, 2.19 Hz), 6.97 (1H, br t, J  4.40 Hz), 6.68 to
6.73 (2H, m), 6.37 (1H, d, J  5.39 Hz), 3.39 to 3.47 (6H, m), 2.64 to 2.71 (6H, m), 2.00 (2H, m). 13C NMR  (ppm)
(CHCl3-d): 24.0, 43.9, 46.1, 53.0, 58.3, 98.7, 108.5, 117.4, 121.6, 124.9, 128.9, 134.8, 149.2, 150.3, 150.5, 152.3,
154.8. ESIMS [M  H] calculated for C21H24ClN5 382.1786, found 382.1.
7-Chloro-N-(3-(4-(pyrimidin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine (compound 23). The ti-
tle compound was prepared from compound 5 (0.30 g, 0.95 mmol), 2-(piperazin-1-yl)pyrimidine (0.17 g,
1.05 mmol), and triethylamine (0.19 g, 1.91 mmol) according to general procedure A. The crude product
was purified by column chromatography on silica, eluting with ethyl acetate-methanol (1:1), to give a
solid (0.16 g, 42%). HPLC tR  6.95 (99% pure). 1H NMR  (ppm) (CH3OH-d4): 8.39 (1H, d, J  5.61 Hz),
8.34 (2H, d, J  4.76 Hz), 8.11 (1H, d, J  8.99 Hz), 7.80 (1H, d, J  2.17 Hz), 7.41 (1H, dd, J  8.98, 2.18
Hz), 6.62 (1H, t, J  4.77 Hz), 6.58 (1H, d, J  5.66 Hz), 3.84 to 3.85 (4H, m), 3.48 (2H, t, J  6.84 Hz), 2.58
to 2.59 (6H, m), 1.98 to 2.03 (2H, m). 13C NMR  (ppm) (CH3OH-d4): 161.5, 157.7, 151.4, 151.1, 148.3, 135.0,
126.2, 124.6, 122.9, 117.4, 109.9, 98.3, 56.1, 52.8, 43.3, 41.1, 24.7. ESIMS [M  H] calculated for C20H24ClN6
383.1741, found 383.1745.
General procedure C for the preparation of compounds 17 and 24 to 27. Compound 16 was
dissolved in acetonitrile and K2CO3 was added, followed by the appropriate halide. The reaction mixtures
were heated to 70°C until thin-layer chromatography (TLC) indicated there was no more compound 16
present. The reaction mixtures were cooled to room temperature and the solvent evaporated. The
residue was partitioned between water and chloroform, and the aqueous layer was further extracted
with chloroform. The combined organic layers were dried and evaporated to leave a crude product,
which was then purified by recrystallization and/or chromatography.
N-(3-(4-Benzylpiperazin-1-yl)propyl)-7-chloroquinolin-4-amine (compound 17). The title com-
pound was prepared according to general procedure C, from compound 16 (1.2 g, 3.9 mmol), benzyl-
bromide (0.74 g, 4.3 mmol), and K2CO3 (0.82 g, 5.9 mmol) in acetonitrile (20 ml) and was heated for 16 h.
The crude product was purified by column chromatography on alumina, eluting with 100% ethyl acetate,
to give a solid (0.4 g, 26%). HPLC tR  7.02 (98%). 1H NMR  (ppm) (CHCl3-d): 8.49 (1H, d, J  5.36 Hz),
7.93 (1H, d, J  2.15 Hz), 7.82 (1H, d, J  8.95 Hz), 7.63 (1H, br t, J  4.02 Hz), 7.35 to 7.36 (5H, m), 7.17
(1H, dd, J  8.92, 2.18 Hz), 6.30 (1H, d, J  5.40 Hz), 3.66 (2H, s), 3.36 (2H, td, J  5.80, 4.09 Hz), 2.62 to
2.64 (10H, m), 1.93 (2H, m). 13C NMR  (ppm) (CHCl3-d): 152.2, 150.6, 149.1, 137.3, 134.6, 129.4, 128.6,
128.4, 127.4, 124.6, 122.5, 117.5, 98.4, 63.2, 58.9, 53.7, 52.9, 44.6, 23.3. ESIMS [M  H] calculated for
C23H27ClN4, 395.14970, found 395.19893.
7-Chloro-N-(3-(4-(5-nitropyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine (compound 24).
The title compound was prepared according to general procedure C from compound 16 (1.0 g, 3.3
mmol), 2-chloro-5-nitropyridine (0.55 g, 3.4 mmol), and K2CO3 (0.54 g, 3.9 mmol) in acetonitrile (15 ml)
and was heated for 1.5 h. The crude product was recrystallized from ethanol to give a solid (1.0 g, 71%).
HPLC tR  8.05 (98.9% pure). 1H NMR  (ppm) (CHCl3-d): 9.07 (1H, d, J  2.79 Hz), 8.54 (1H, d, J  5.34
Hz), 8.24 (1H, dd, J  9.46, 2.79 Hz), 7.95 (1H, d, J  2.14 Hz), 7.73 (1H, d, J  8.92 Hz), 7.31 (1H, dd, J 
8.88, 2.16 Hz), 6.78 (1H, br t, J  4.42 Hz), 6.61 (1H, d, J  9.49 Hz), 6.39 (1H, d, J  5.37 Hz), 3.89 (4H,
m), 3.44 (2H, td, J  6.10, 4.47 Hz), 2.67 (6H, m), 2.01 (2H, m). 13C NMR  (ppm) (CHCl3-d): 160.3, 152.2,
150.2, 149.1, 146.4, 135.4, 134.8, 133.2, 128.9, 125.0, 121.3, 117.4, 104.6, 98.8, 58.1, 53.2, 44.9, 43.7, 24.1.
7-Chloro-N-(3-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine (com-
pound 25). The title compound was prepared according to general procedure C from compound 16 (1.0
g, 3.3 mmol), 2-chloro-5-(trifluoromethyl)pyridine (0.63 g, 3.4 mmol), and K2CO3 (0.54 g, 3.9 mmol) in
acetonitrile (15 ml) and was heated for 1.5 h. The crude product was recrystallized from ethanol to give a
solid (0.73 g, 56%). 1H NMR  (ppm) (CHCl3-d): 8.53 (1H, d, J  5.35 Hz), 8.35 to 8.52 (1H, m), 7.94 (1H, d, J 
2.15 Hz), 7.76 (1H, d, J  8.94 Hz), 7.68 (1H, m), 7.25 to 7.29 (~1H, dd, J  8.98, 2.14 Hz), 7.04 (1H, br t, J 
4.28 Hz), 6.68 (1H, d, J  9.00 Hz), 6.37 (1H, d, J  5.39 Hz), 3.76 to 3.77 (4H, m), 3.43 (2H, td, J  6.01, 4.35
Hz), 2.66 to 2.67 (6H, m), 1.99 to 2.00 (2H, m). 13C NMR  (ppm) (CHCl3-d): 160.2, 152.3, 150.3, 149.2, 145.8 (q,
JF  4.19 Hz), 134.71, 134.68 (q, JF  3.48 Hz), 128.9, 124.9, 124.5 (q, JF  270 Hz), 121.6, 117.4, 115.7 (q,
JF  32.8 Hz), 105.6, 98.7, 58.4, 53.3, 44.8, 44.0, 23.9. 19F NMR  (ppm) (DMSO-d6): 59.3. ESIMS [M  H]
calculated for C22H23ClF3N5, 450.16668; found 450.16557.
7-Chloro-N-(3-(4-(3,5-dinitropyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine (compound
26). The title compound was prepared according to general procedure C from compound 16 (1.0 g, 3.3
mmol), 2-chloro-3,5-dinitropyridine (0.7 g, 3.4 mmol), and K2CO3 (0.54 g, 3.9 mmol) in acetonitrile (15 ml)
and was heated for 1.5 h. The crude product was recrystallized from ethanol to give a solid (0.5 g, 32%).
1H NMR  (ppm) (CHCl3-d): 9.13 (1H, d, J  2.45 Hz), 8.94 (1H, d, J  2.45 Hz), 8.54 (1H, d, J  5.35 Hz),
7.97 (1H, d, J  2.15 Hz), 7.73 (1H, d, J  8.93 Hz), 7.40 (1H, s), 6.53 (1H, s), 6.40 (1H, d, J  5.39 Hz), 3.78
(4H, m), 3.45 (2H, m), 2.70 to 2.65 (6H, m), 2.00 (2H, m). 13C NMR  (ppm) (CHCl3-d): 162.2, 161.3, 152.2,
149.8, 146.2, 135.4, 133.8, 132.2, 128.9, 125.5, 121.3, 117.4, 104.6, 98.8, 58.1, 53.2, 44.9, 44.7, 24.2.
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The title compound was prepared according to general procedure C from compound 16 (1.0 g, 3.3
mmol), 2,4-dinitrofluorobenzene (0.64 g, 3.4 mmol), and K2CO3 (0.54 g, 3.9 mmol) in acetonitrile (15 ml)
and was heated for 1.5 h. The crude product was recrystallized from ethanol to give a solid (0.94 g, 61%).
HPLC tR  8.90 (99%). 1H NMR  (ppm) (CHCl3-d): 8.72 (1H, d, J  2.70 Hz), 8.54 (1H, d, J  5.33 Hz), 8.30
(1H, dd, J  9.25, 2.72 Hz), 7.95 (1H, d, J  2.14 Hz), 7.73 (1H, d, J  8.91 Hz), 7.34 (1H, dd, J  8.88, 2.16
Hz), 7.15 (1H, d, J  9.27 Hz), 6.62 (1 H, br t, J  4.48 Hz), 6.39 (1H, d, J  5.37 Hz), 3.43 (2H, td, J  6.14,
4.54 Hz), 3.36 to 3.39 (4H, m), 2.72 to 2.73 (4H, m), 2.70 (2H, t, J  5.74 Hz), 2.00 (2H, m). 13C NMR  (ppm)
(CHCl3-d): 152.2, 150.1, 149.2, 149.2, 138.9, 138.6, 134.8, 129.0, 128.4, 125.0, 123.7, 121.3, 119.6, 117.4, 98.8,
57.8, 52.9, 50.7, 43.5, 24.2. ESIMS [M  H] calculated for C22H23ClN6O4, 471.15313; found 471.15421.
Inhibition of P. falciparum growth. CQS (D6) and CQR (Dd2 and 7G8) P. falciparum maintained
continuously in culture were used (38). Asynchronous cultures were diluted with uninfected red blood cells
(Lampire Biological Laboratories) and complete medium (RPMI 1640 with 0.5% AlbuMAX II) to achieve 0.2%
parasitemia and 2% hematocrit. In 96-well microplates, CQ (positive control) or RCQ diluted in complete
medium from 10 mM stock in dimethyl sulfoxide (DMSO) was added to the cell mixture to yield triplicate wells
with drug concentrations ranging from 0 to 104 M in a final well volume of 100 l. After 72 h of incubation
under standard culture conditions, plates were harvested and read by the SYBR green I fluorescence-based
method (38) using a 96-well fluorescence plate reader (Gemini-EM; Molecular Devices), with excitation and
emission wavelengths at 497 and 520 nm, respectively. The fluorescence readings were plotted against
log(drug), and the IC50s were obtained from curve fitting performed by nonlinear regression using either
Prism (GraphPad) or Excel (Microsoft) software. The values obtained for each cell line are normalized to CQ
values of 6.9 nM for D6, 102 nM for Dd2, and 106 nM for 7G8.
In vitro heme binding and -hematin inhibition. For heme-drug binding studies, a 1 mM stock
solution of chloroquine or PL compound was prepared in distilled water, methanol, or DMSO, depending on
solubility, and sonicated to ensure complete dissolution. A 5 mM stock solution of heme was prepared by
dissolving heme chloride in 0.1 mM NaOH by incubation at 37°C for 30 min. The solution was stored at 4°C
for no more than 1 month. At the beginning of each experiment, the stock heme solution was diluted to 5
M in phosphate buffer (100 mM, pH 5.7) and allowed to equilibrate for 4 h. The 4-h equilibration allowed
for the initial heme absorbance to stabilize prior to beginning the titration. Optical titrations with each
compound were performed by successive addition of aliquots of its stock solution to the 5 M heme solution.
The pH was monitored throughout the procedure with only negligible (0.05 pH unit) changes. Equilibrium
binding constants were determined by nonlinear least-squares analysis (39).
Hemin chloride (16.3 mg) was dissolved in 1 ml of DMSO. The solution was passed through a 0.2-m-pore
membrane filter to remove insoluble particles and kept at 4°C for no more than 1 month as a stock
solution (40). In order to determine the heme concentration of the stock solution, a sample was diluted
in 2.5% sodium dodecyl sulfate in 0.1 M NaOH and an absorbance reading was taken at 400 nm. The
heme concentration was calculated using Beer’s law with a molar absorptivity () of 105 mol liter1 cm1.
The optimal heme and Tween 20 concentrations for promoting heme crystallization were calculated
by the procedure described by Huy et al. (41). The RCQ compounds were screened for their
inhibitory capacity, and IC50s were determined. Assays were run in duplicate. A series of solutions
were made consisting of 300 l of various concentrations of the compound under study in 700 l
of 1 M distilled acetate buffer, 300 l of a 200 M heme solution freshly buffered by 1 M sodium
acetate (pH 4.8), and 200 l of 0.0375 g/liter Tween 20 solution. This provided a final 40 M heme
solution buffered by 0.67 M sodium acetate at pH 4.8 and 0.0005 g/liter Tween 20, with the test
compound ranging in concentration from 0 to 1,000 M. The mixtures were incubated for 24 h at 37°C
(42) and then mixed and transferred to a cuvette for a 415/630-nm absorbance reading. IC50s were calculated
by (Dmax  Dinitial)/2, where Dmax represents the lowest concentration of compound under study to provide
maximal absorbance readings, indicating maximal free heme, and Dinitial represents the lowest concentration
of drug providing any increase in absorbance over a solution with no drug.
In vivo 3-day suppressive test. Female CF-1 mice, at 4 to 5 weeks of age, were injected intrave-
nously with 106 erythrocytes infected with P. yoelii (43–45). The following day, and then daily for a total
of 3 doses, 5 mice each were administered the appropriate dose of the compound by gavage and
evaluated by direct microscopic analysis of Giemsa-stained blood smears (46) 1 day after the final dose.
The Portland State University Institutional Animal Care and Use Committee approved the protocols
involving animals used in this study.
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